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Bacteria and archaea use the CRISPR–Cas system as an adaptive response
against infection by foreign nucleic acids. Owing to its remarkable flexibility, this
mechanism has been harnessed and adopted as a powerful tool for genome
editing. The CRISPR–Cas system includes two classes that are subdivided into
six types and 19 subtypes according to conservation of the cas gene and loci
organization. Recently, a new protein with endonuclease activity belonging to
class 2 type V has been identified. This endonuclease, termed Cpf1, in complex
with a single CRISPR RNA (crRNA) is able to recognize and cleave a target
DNA preceded by a 50-TTN-30 protospacer-adjacent motif (PAM) complemen-
tary to the RNA guide. To obtain structural insight into the inner workings of
Cpf1, the crystallization of an active complex containing the full extent of the
crRNA and a 31-nucleotide dsDNA target was attempted. The gene encoding
Cpf1 from Francisella novicida was cloned, overexpressed and purified.
The crRNA was transcribed and purified in vitro. Finally, the ternary
FnCpf1–crRNA–DNA complex was assembled and purified by preparative
electrophoresis before crystallization. Crystals belonging to space group C2221,
with unit-cell parameters a = 85.2, b = 137.6, c = 320.5 A˚, were obtained and
subjected to preliminary diffraction experiments.
1. Introduction
The prokaryotic adaptive immune system CRISPR–Cas
(clustered regularly interspaced short palindromic repeats and
CRISPR-associated proteins) provides many bacteria and
most archaea with a functional defence mechanism against
foreign genetic material such as plasmids and phages
(Marraffini, 2015; Wright et al., 2016).
Ever since the early characterization of the system, its
simplicity and versatility have led to the development of a
thriving field that has spread out to essentially every discipline
from molecular and cell biology to genetics. Initially described
simply as a theoretical concept (Mojica et al., 2005), the
CRISPR–Cas system has experienced an unstoppable rise,
unfolding as a boundless tool for genome editing (Jinek et al.,
2012), and its immense versatility can be exploited for multiple
applications (Doudna & Charpentier, 2014). Through RNA-
guided recognition, the CRISPR–Cas system can bind and
cleave virtually any given target DNA sequence (Marraffini,
2015). Structural studies have been crucial in revealing the
intimate details of the mechanism of interaction between the
nuclease and the substrate (Wiedenheft et al., 2009), enabling
structure-guided engineering to improve target specificity and
to alter the protospacer-adjacent motif (PAM) requirements
(Kleinstiver et al., 2016; Slaymaker et al., 2016).
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According to their molecular architectures, the different
members of the CRISPR–Cas system have been classified into
two classes: class 1 members encompass several effector
proteins, whereas class 2 systems use a single element
(Makarova et al., 2015). Cpf1 (CRISPR from Prevotella and
Francisella) has been described as a new member of the class 2
type V CRISPR–Cas endonucleases that is present in a
number of bacterial genomes (Zetsche et al., 2015) and
possesses a range of particular features that have led to its
emergence as an encouraging choice for genome-editing
applications (Fig. 1a; Fonfara et al., 2016). Firstly, Cpf1 uses
42–44 nt RNA and an additional tracer RNA (tracrRNA) is
not needed (Zetsche et al., 2015); this RNA guide is signifi-
cantly shorter and simpler than the RNA pair [CRISPR RNA
(crRNA) and tracrRNA, or a single-guide RNA (sgRNA) in
engineered variants] required by Cas9 (Deltcheva et al., 2011).
Moreover, Cpf1 possesses the ability to process its own RNA
template, which is cleaved in a sequence-dependent and
structure-dependent fashion from the spacer repeat sequence
(Yamano et al., 2016). Secondly, the short and conserved PAM
recognized by Cpf1 is a T-rich sequence (Zetsche et al., 2015)
instead of the G-rich motif needed by CRISPR–Cas
(Deltcheva et al., 2011), which might be useful for targeting A/
T-rich genomes. The final, and probably the most interesting,
unique feature of Cpf1 is the creation of a staggered double-
strand break, with a 4 or 5 nt 50-overhang in its PAM-distal
target site (Zetsche et al., 2015), as opposed to the blunt ends
Figure 1
FnCpf1, crRNA and template DNA. (a) Domain organization of FnCpf1. (b) SDS–PAGE gel showing purified wild-type (wt) FnCpf1 and
selenomethionine-derivatized FnCpf1 (SeMet FnCpf1). Lanes M contain molecular-weight markers (labelled in kDa). (c) Schematic representation of
the CRISPR RNA (crRNA) and the target and nontarget (PAM) DNA strands used in assembly of the complex. (d) Native PAGE gel showing the
fractions corresponding to the Cpf1–crRNA–DNA complex purified by gel-filtration chromatography. (e) Separation profile of the ternary Cpf1–RNA–
DNA complex by gel-filtration chromatography (see x2). ( f ) Native PAGE gel showing the purification of the FnCpf1 complex by preparative vertical-
tubular electrophoresis (see x2). Native PAGE gel showing the fractions corresponding to the Cpf1–crRNA–DNA complex purified by gel-filtration
chromatography; the fractions pooled and used for crystallization are indicated.
generated by Cas9 within the PAM-proximal target site
(Garneau et al., 2010). For these reasons, Cpf1 is emerging as
an upgraded version of the CRISPR–Cas system, which may
supplement the growing genome-editing toolbox and open up
a wealth of new biotechnological and therapeutic applications.
Recent structural studies have started to shed light on the
molecular mechanisms of catalysis by Cpf1. In these studies,
the crystal structures of Cpf1 from Lachnospiraceae bacterium
(LbCpf1; Dong et al., 2016) in complex with crRNA and from
Acidoaminococcus sp. (AsCpf1; Yamano et al., 2016) in
complex with crRNA and a truncated portion of target DNA
containing the 4 nt PAM sequence have been solved.
However, the structures of these complexes offer a snapshot
of the target readout and therefore still lack the mechanistic
insights necessary to fully describe how the recognition,
unzipping and cleavage of the target DNA are achieved.
Therefore, we set out to resolve this question by expressing,
purifying, reconstituting and assembling FnCpf1 with its
crRNA and a 31 bp dsDNA target in vitro.
2. Materials and methods
2.1. Macromolecule production
2.1.1. Protein expression and purification. The gene
encoding full-length (residues 1–1300) Cpf1 from F. novicida
U112 (FnCpf1) was obtained from Addgene (plasmid No.
69975, plasmid name pY003 -pFnCpf1_min). The target locus
was amplified by PCR using the specific primers FnCpf1-
Forward (CGTATGTTAGGAGGTCTTTCATATGTCAAT-
TTATCAAG) and FnCpf1-Reverse (GATCTGGATCCGTT-
ATTCCTATTCTGCACGAACTC) to clone the PCR product
into the expression vector pET-21a (catalogue No. 69740-3,
EMD Biosciences). The PCR product and the destination
vector were subjected to double digestion with the restriction
enzymes NdeI and BamHI (New England Biolabs). The
digestion products were gel-purified and ligated together using
T4 DNA ligase (New England Biolabs) to generate a pET21-
FnCpf1 plasmid encoding FnCpf1 fused to a C-terminal
hexahistidine tag (His6 tag; Table 1).
Escherichia coli BL21 Star (DE3) cells containing the
pRare2 plasmid (which supplies seven tRNAs recognizing rare
codons) were transformed with the target construct pET21-
FnCpf1. A single colony carrying both plasmids was inocu-
lated into 5 ml Luria broth (LB) containing 50 mg ml1
ampicillin and 25 mg ml1 chloramphenicol and incubated
overnight at 310 K with shaking at 200 rev min1. 1 ml of the
overnight culture was transferred into 1 l fresh LB containing
50 mg ml1 ampicillin and 25 mg ml1 chloramphenicol and
incubated at 310 K with shaking at 200 rev min1 until an
OD600 of 0.8 was reached. The culture was then induced by
adding 1 mM isopropyl -d-1-thiogalactopyranoside (IPTG)
and incubated at 310 K for 3 h before the cells were collected
by centrifugation at 9000g for 20 min at 277 K and stored at
193 K until further use. To prepare selenomethionine-
substituted protein, cells were grown in SelenoMethionine
Medium Complete (Molecular Dimensions) including
40 mg ml1 selenomethionine, 50 mg ml1 ampicillin and
25 mg ml1 chloramphenicol at 310 K with shaking at
200 rev min1. When the culture reached an OD600 of 0.8,
protein expression was induced with 1 mM IPTG and incu-
bation at 310 K for 3 h before the culture was harvested by
centrifugation at 9000g for 20 min at 277 K.
The cell pellets were defrosted and resuspended in lysis
buffer [50 mM bicine pH 8.0, 150 mM KCl, one tablet of
cOmplete Inhibitor Cocktail, EDTA-free (Roche) per 50 ml,
50 U ml1 Benzonase, 1 mg ml1 lysozyme, 0.5 mM TCEP].
After cell disruption using a French press, cell debris and
insoluble particles were removed by centrifugation at 10 000g
at 277 K. The supernatant was loaded onto a 5 ml Crude
HisTrap column (GE Healthcare) equilibrated in buffer A
(50 mM bicine pH 8.0, 150 mM KCl, 0.5 mM TCEP). After the
sample had been loaded, the column was washed with buffer A
containing 5 mM imidazole to prevent nonspecific binding of
contaminants to the resin. Elution was performed by applying
a step gradient of 10, 25, 50 and 100% buffer B (50 mM bicine
pH 8.0, 150 mM KCl, 0.5 mM TCEP, 1 M imidazole). Enriched
protein fractions corresponding to 25 and 50% buffer B were
pooled together and applied onto a 5 ml HiTrap Heparin HP
column (GE Healthcare) equilibrated with buffer A. The
protein was eluted with a linear gradient of 0–100% buffer H
(50 mM bicine pH 8.0, 1 M KCl, 0.5 mM TCEP) in ten column
volumes. Protein-rich fractions were collected and concen-
trated (using 100 kDa MWCO Centriprep Amicon Ultra
devices) and subsequently loaded onto a HiLoad 16/60 200
Superdex column (GE Healthcare) equilibrated in buffer A.
The protein peaks were concentrated (using 100 kDa MWCO
Centriprep Amicon Ultra devices), flash-frozen in liquid
nitrogen and stored at 193 K. The protein concentration was
determined using the theoretical molar extinction coefficient
at 280 nm calculated from the amino-acid composition. An
overloaded SDS–PAGE stained with SimplyBlue (Invitrogen)
displayed a highly pure protein preparation.
2.1.2. RNA transcription. DNA oligonucleotides corre-
sponding to the reverse-complemented sequence of the target
site (67 bases in length) and a short T7 priming sequence (24
bases in length) were purchased from Integrated DNA Tech-
nologies (IDT). The oligonucleotides were annealed at a final
concentration of 20 mM in annealing buffer consisting of
150 mM KCl by heating the mixture to 368 K for 10 min
followed by a cool ramp to 277 K over 10 min. This partial
DNA duplex was used as a template in a transcription reaction
carried out by HiScribe T7 Quick High Yield RNA Synthesis
(NEB). The reaction was stopped using 2 stop solution
(50 mM EDTA, 20 mM Tris–HCl pH 8.0, 8 M urea) and the
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Table 1
Macromolecule production.
Source organism F. novicida U112
DNA source Addgene (plasmid No. 69975, plasmid name pY003
-pFnCpf1_min)
Forward primer CGTATGTTAGGAGGTCTTTCATATGTCAATTTATCAAG
Reverse primer GATCTGGATCCGTTATTCCTATTCTGCACGAACTC
Expression vector pET-21a
Expression host BL21 Star (DE3)
RNA was denatured at 368 K for 10 min. The transcription
product was purified by preparative electrophoresis with a
Bio-Rad Model 491 PrepCell apparatus equipped based on a
previously described method (Cunningham et al., 1996) with
some modifications. Briefly, a PrepCell was used with a 37 mm
internal diameter gel tube using a 9 cm tall 1 TBE (178 mM
Tris–borate, 4 mM EDTA) 15% (19:1) polyacrylamide/7 M
urea gel at room temperature. The running buffer 1 TBE
and the core gel were prewarmed to 323 K. The gel was run at
14 W constant power for 60 min prior to loading the de-
natured sample. The sample was eluted at 1 ml min1 in
nuclease-free water. The elution was monitored and
fractionated. 1 TBE/15% polyacrylamide/7 M urea gel was
used to identify the fractions containing the correct RNA. The
fractions were then pooled together and concentrated using
Vivaspin 20 3000 MWCO to an OD260 of 30–35.
2.1.3. Complex formation and purification by gel-filtration
chromatography and vertical-tubular electrophoresis. For the
formation of the complex, the purified FnCpf1 protein was
mixed first with crRNA and incubated for 30 min at 293 K and
then with the target DNA duplex (target and nontarget DNA
oligonucleotides were purchased from IDT) and incubated for
a further 60 min at 368 K (the final protein:RNA:DNA molar
ratio was 1:1.3:1.7) in reconstitution buffer consisting of
81 mM KCl, 38 mM bicine pH 8.0, 5 mM MgCl2 with a final
reaction volume of 960 ml.
The reconstituted complex was purified using a HiLoad
16/60 200 Superdex column (GE Healthcare) equilibrated
with buffer E consisting of 150 mM KCl, 50 mM bicine pH 8.0,
0.5 mM TCEP. The fractions were loaded onto a native PAGE
gel and those containing the complex were pooled and
concentrated to 7 mg ml 1.
Aternatively, the assembled Cpf1–crRNA–DNA ternary
complex was purified by preparative electrophoresis using a
Bio-Rad Model 491 PrepCell apparatus equipped with a
37 mm internal diameter gel tube using a 6 cm tall 8%(w/v)
nondenaturing polyacrylamide gel (19:1 ratio of acrylamide:
bis-acrylamide) at 277 K. After a 2 h prerun under constant
buffer recirculation, the complex was loaded onto the
preparative gel. Electrophoresis was performed at a constant
power of 10 W using 0.5 TBE (89 mM Tris–borate, 2 mM
EDTA) as the running buffer and eluting at a flow rate of
1 ml min1 in buffer E consisting of 150 mM KCl, 50 mM
bicine pH 8.0, 0.5 mM TCEP using an A¨KTAprime system
attached to the PrepCell. Highly pure and homogeneous
complex was separated from free DNA and high-molecular-
weight aggregates and immediately concentrated to 7 mg ml1
with a Vivaspin 20 50000 MWCO centrifugal concentrator for
subsequent crystallization experiments.
2.2. Size-exclusion chromatography coupled with static laser
light scattering (SEC-MALS)
We verified the homogeneity of the ternary FnCpf1–
crRNA–target DNA complex by multi-angle light scattering
connected in line with SEC (SEC-MALS). SEC-MALS
experiments were performed on a Dionex HPLC system with
the UV detector linked to a Wyatt DAWN8+ HELEOS eight-
angle light-scattering detector and a Wyatt Optilab T-rEX
refractive-index detector. SEC was performed on a Superdex
200 10/300 GL column (GE Healthcare) in 50 mM bicine pH
8.0, 150 mM KCl, 0.5 mM TCEP. 50 ml of the Cpf1 complex
was injected at 1 mg ml1 concentration at a 0.5 ml min1 flow
rate. The Astra software (v.6.1.5) was used to collect data from
the ultraviolet, refractive-index and light-scattering detectors
and to analyse the data using UV extinction coefficients at
280 nm of 0.951 ml mg1 cm1 (protein) and 10 ml mg1 cm1
(nucleic acid) and refractive-index increments (dn/dc) of
0.185 ml g1 (protein) and 0.170 ml g1 (nucleic acid).
2.3. Crystallization
Initial crystallization screening was performed at 293 K by
the sitting-drop vapour-diffusion method, testing a collection
of commercially available crystallization screens (The JCSG+
Suite and The Protein Complex Suite from Qiagen, Crystal
Screen HT from Hampton Research and Wizard Cryo 1 & 2
from Rigaku Reagents).
In these experiments, 100 nl drops of the Cpf1 complex at
7 mg ml1 were mixed with the same volume of reservoir
solution and set up in 96-well iQ plates (TTP Labtech; 70 ml
reservoir), testing three different protein:reservoir volume
ratios (1:1, 1.2:1 and 1:1.2) using a Mosquito Crystal robot
(TTP Labtech, Melbourn, England). The plates were stored
and crystal growth was monitored at 293 K using an auto-
mated Rock Imager 1000 imaging system and the Rock Maker
software package for data management (Formulatrix,
Bedford, Massachusetts, USA).
After 5 d of incubation, the extensive initial screening
rendered a unique hit from well B2 [0.35 M sodium thiocya-
nate, 20%(w/v) PEG 3350] of the JCSG-plus HT-96 screen
(Molecular Dimensions). These initial plate-like crystals
formed after 3 d of incubation, only achieving modest
dimensions (20  20  5 mm). The protein content in the
crystals was verified using the UV-sensitive camera provided
by the imager system. Following initial hit identification,
crystal growth was optimized using a Dragonfly screen opti-
mizer (TTP Labtech). Further optimization was carried out by
setting up 0.25 ml of complex mixed with 0.25 ml of reservoir
solution in a hanging-drop setup on 96-well MRC plates
(Molecular Dimensions; 90 ml reservoir), rendering large
plate-like crystals of around 200  200  20 mm (Table 2).
Prior to diffraction experiments, SDS–PAGE and silver-
staining analysis of washed and dissolved crystals revealed the
presence of all of the components in the ternary FnCpf1–
RNA–DNA complex.
2.4. Data collection and processing
Crystals were mounted on CryoLoops (Hampton Research)
and soaked into a solution composed of the mother liquor
supplemented with 30% methyl-2,4-pentanediol prior to flash-
cooling using a CryoStream (Oxford Cryosystems). Initial
diffraction experiments and data collection were carried out
using an EIGER detector on the X06SA beamline, Swiss Light
research communications
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Source, Villigen, Switzerland. X-ray images were recorded
with an EIGER detector using the fine-slicing method
(Dauter, 1999) with 0.2 oscillations at 100 K, a wavelength of
1.0 A˚ and a crystal-to-detector distance of 386 mm (see
Table 1 for data-collection details and statistics). X-ray
diffraction data sets were collected to a resolution of 2.9 A˚
from native protein crystals. Data processing and scaling were
accomplished with XDS (Kabsch, 2010) and AIMLESS
(Evans & Murshudov, 2013) as implemented in autoPROC
(Vonrhein et al., 2011). Based on the diffraction pattern, these
crystals belonged to the orthorhombic space group C2221,
with unit-cell parameters a = 85.2, b = 137.6, c = 320.5 A˚,
 =  =  = 90 (Table 3). To determine the packing of the
FnCpf1 ternary complex in the asymmetric unit of the crystal,
we calculated the Matthews coefficient (Matthews, 1968),
which yielded a VM of 2.35 A˚
3 Da1, corresponding to a
solvent content of 48%, with one complex in the asymmetric
unit. We attempted to solve the structure of the ternary
complex by the molecular-replacement method using
LbCpf1 and AsCpf1 without success, suggesting that major
conformational changes may occur in the ternary complex.
Therefore, selenomethionine-derivatized FnCpf1 was
produced to obtain experimental phases using the MAD
phasing method.
3. Results and discussion
The previous structures of Cpf1–DNA complexes used a
partial double-stranded target; this artificial target stalls the
enzyme, which is unable to perform the cleavage reaction
because one of the DNA strands is missing (Yamano et al.,
2016). To better understand the catalysis of the Cpf1–crRNA
research communications
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Table 2
Crystallization.
Method Sitting-drop vapour diffusion
Plate type 96-well MRC
Temperature (K) 293
Protein concentration (mg ml 1) 7
Buffer composition of protein
solution
150 mM KCl, 50 mM bicine pH 8.0,
0.5 mM TCEP
Composition of reservoir solution 0.35 M sodium thiocyanate, 20%(w/v)
PEG 3350
Volume and ratio of drop 0.5 ml, 1:1 ratio
Volume of reservoir (ml) 70
Table 3
Data collection and processing.
Values in parentheses are for the outer shell.
Diffraction source X06SA, SLS
Wavelength (A˚) 1.0
Temperature (K) 100
Detector EIGER 16M X [133 Hz]
Crystal-to-detector distance (mm) 386
Rotation range per image () 0.2
Total rotation range () 180
Exposure time per image (s) 1
Space group C2221
a, b, c (A˚) 85.2, 137.6, 320.5
, ,  () 90
Mosaicity () 0.4
Resolution range (A˚) 80.12–2.95 (2.96–2.95)
Total No. of reflections 267815 (2811)
No. of unique reflections 39708 (405)
Completeness (%) 98 (98)
Multiplicity 6.7 (7.0)
CC1/2 0.99 (0.35)
hI/(I)i 7.0 (0.9)
Rmeas 0.26 (1.75)
Overall B factor from Wilson plot (A˚2) 65.4
Figure 2
SEC-MALS. The molecular weight of the FnCpf1–crRNA–DNA complex was determined by SEC-MALS-RI-UV. The Rayleigh ratio at 90 (LS 5;
continuous line), ultraviolet absorbance (UV; dashed line) and weight-average molar masses (MW) for the complex (red), protein (green) and nucleic
acid (blue) are plotted versus the elution volume, showing constant molar-mass values over the entire peak width.
enzyme, we overexpressed and purified FnCpf1 (Fig. 1a) in
both native and selenomethionine-derivatized forms (Fig. 1b).
We used a Bio-Rad Model 491 PrepCell in denaturant
conditions to purify the crRNA. We then assembled the
complex using the purified components (protein and crRNA)
and the target DNA duplex (Fig. 1c). The traditional purifi-
cation of the complex by size-exclusion chromatography using
a Superdex 200 16/60 (GE Healthcare) produced an appar-
ently homogeneous complex sample (Fig. 1d); further analysis
by native electrophoresis (Fig. 1e) indicated that the sample
contained different species, most likely owing to alternative
conformations or catalytic states. Consequently, attempts to
crystallize this ternary complex obtained by size-exclusion
chromatography were unsuccessful. We then used vertical-
tubular native electrophoresis for the first time to purify the
FnCpf1–crRNA–DNA target complex with a higher quality
(Fig. 1f). In contrast to classic size-exclusion chromatography,
our purification method overcomes the heterogeneity issues
described above, providing a highly homogeneous sample
(Fig. 1f). A SEC-MALS experiment showed that this purified
complex is homogeneous (Fig. 2). Furthermore, the superior
purity of the Cpf1–crRNA–DNA ternary complex obtained by
preparative native electrophoresis was confirmed by its
successful crystallization: the complex forms large plate-like
crystals of around 200  200  20 mm in size (Fig. 3). From the
diffraction pattern (Fig. 3d), these crystals belonged to the
orthorhombic space group C2221, with unit-cell parameters a
= 85.2, b = 137.6, c = 320.5 A˚,  =  =  = 90 (Table 3). Thus,
this technique offers the possibility of purifying CRISPR–Cas
ternary complexes at specific states of the enzymatic process,
providing a powerful tool to investigate the precise molecular
events leading to target recognition and catalysis by these
RNA-guided endonucleases.
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